FCGR3A and myeloid sarcoma: Recombinant interferon-β (IFN-β), like GA a basic disease-modifying treatment for MS, has been reported to induce in MS patients a phenotypic shift from CD14+CD16+ towards CD14++CD16+ monocytes which simply means that the CD14 expression is increased by IFN-β [44].